Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2026 Jan 30.
doi: 10.1038/s41433-026-04260-3. Online ahead of print.

SPECTRUM: early clinical experience from the first global real-world study of aflibercept 8 mg in patients with neovascular age-related macular degeneration

Clare Bailey  1 , Clemens Lange  2   3 , Varun Chaudhary  4 , Paolo Lanzetta  5   6 , Hassiba Oubraham  7 , Martin Kirchner  8 , Tobias Machewitz  9 , Helmut Allmeier  10 , Xin Zhang  10 , Zoran Hasanbasic  10 , Marion R Munk  11   12   13 ; SPECTRUM study investigators
Affiliations

SPECTRUM: early clinical experience from the first global real-world study of aflibercept 8 mg in patients with neovascular age-related macular degeneration

Clare Bailey et al. Eye (Lond). .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests: CB: Honoraria from Alimera Sciences, Apellis, Bayer, and Roche; and has served on advisory boards for Alimera Sciences, Apellis, Bayer, Boehringer Ingelheim, Janssen, and Roche. CL: Honoraria from Apellis, Bayer, Biogen, and Novartis. VC: Consulting fees from EyePoint Pharmaceuticals; grants from Bayer, Novartis, and Roche; serves on advisory boards for Apellis, Bayer, Boehringer Ingelheim, EyePoint Pharmaceuticals, Novartis, and Roche; and is a member of the journal’s Editorial Board at the time of submission. PL: Consulting fees from 4DMT, Aerie Pharmaceuticals, Adverum, Allergan, Annexon, Apellis, Bausch + Lomb, Bayer, Biogen, Boehringer Ingelheim, EyePoint Pharmaceuticals, Genentech, I-Care, Novartis, Ocular Therapeutix, Outlook Therapeutics, Roche, and TowardPi. HO: Consulting fees from AbbVie, Bayer, Novartis, and Roche. MK and TM: Employees and stockholders of Bayer AG. HA and ZH: Employees of Bayer Consumer Care AG. XZ: Stockholder and former employee of Bayer Consumer Care AG. MRM: Consulting fees for AbbVie, Alcon, Alimera, Allergan, Amgen, Apellis Pharmaceuticals, Astellas, Aviceda Therapeutics, Bayer, Boehringer Ingelheim, Dandelione, Evolve Medical Education, eye. gnos consulting, EyePoint Pharmaceuticals, GenSight Biologics, Isarna Therapeutics, Iveric Bio, Kubota, LumiThera, Novartis, Ocular Therapeutix, Oculis, OcuTerra Therapeutics, OD-OS, ONL Therapeutics, RetinAI, Roche, Sitalis, UBS analytics, and Zeiss.

References

    1. Lanzetta P, Korobelnik JF, Heier JS, Leal S, Holz FG, Clark WL, et al. Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial. Lancet. 2024;403:1141–52. - DOI - PubMed
    1. Wykoff CC, Brown DM, Reed K, Berliner AJ, Gerstenblith AT, Breazna A, et al. Effect of high-dose intravitreal aflibercept, 8 mg, in patients with neovascular age-related nacular degeneration: the Phase 2 CANDELA randomized clinical trial. JAMA Ophthalmol. 2023;141:834–42. - DOI - PubMed - PMC
    1. ClinicalTrials.gov. The SPECTRUM study: an observational study to learn more about how well aflibercept 8 mg works in treating visual impairment due to neovascular age-related macular degeneration or diabetic macula edema. 2023. https://clinicaltrials.gov/study/NCT06075147 .

LinkOut - more resources